消息面上，11月以来，全国流感活动快速上升，北京已迈入呼吸道传染病高发期。有数据显示，奥司他 韦近7天销量暴涨237%，速福达（玛巴洛沙韦）涨幅达180%，美团买药平台数据更显示，11月以来北 京甲乙流特效药环比增长超130%，其中速福达增长超110%，磷酸奥司他韦颗粒增长超85%。另据阿里 健康平台数据，近两周（11月10日—11月23日）流感应季药品的关注度和购买量均有明显提升，其中流 感抗病毒药物购买人数呈现超500%的环比增长。 机构表示，近期流感活动度持续攀升，当前已攀升至近2022年以来同期高位，流感用药需求增加，关注 流感高发带来的呼吸系统用药需求增长。 生物疫苗概念25日盘中震荡走高，截至发稿，金迪克20%涨停，华兰疫苗涨超10%，海南海药亦涨停， 一品红涨超9%，以岭药业涨逾5%。 ...

来源：新浪证券-红岸工作室 11月25日，海普瑞涨0.77%，成交额3728.31万元，换手率0.25%，总市值173.14亿元。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-136.32万，占比0.04%，行业排名113/159，连续3日被主力资金减仓；所属行业主 ...

2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 来源：新浪证券-红岸工作室 11月21日，海普瑞跌4.14%，成交额5327.83万元，换手率0.36%，总市值169.77亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 技术面：筹码平均交易成本为11.59元 该股筹码平均交易成本为11.59元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位11.54，注意 支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 资料显示，深圳市海普瑞药业集团股份有限公司位于广东省深圳市南山区松坪 ...

1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 来源：新浪证券-红岸工作室 11月20日，海普瑞涨0.42%，成交额3923.48万元，换手率0.26%，总市值177.10亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 区间今日近3日近5日近10日近20日主力净流入-169.92万-820.60万-879.98万-1334.90万-1 ...

Core Viewpoint - The article discusses the recent performance and business operations of Haiprime, highlighting its position in the pharmaceutical industry and the impact of currency depreciation on its revenue [2][3]. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][7]. - The company's main revenue sources include formulations (63.06%), CDMO services (18.59%), and heparin sodium and low molecular weight heparin raw materials (16.05%) [7]. Financial Performance - For the period from January to September 2025, Haiprime reported a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - As of September 30, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On November 17, Haiprime's stock price fell by 1.67%, with a trading volume of 49.2036 million yuan and a turnover rate of 0.32%, bringing the total market capitalization to 18.121 billion yuan [1]. - The stock has seen a net inflow of 1.2514 million yuan from major investors today, with no significant trend in buying or selling observed [4][5]. Technical Analysis - The average trading cost of Haiprime's shares is 11.59 yuan, with the stock price approaching a resistance level of 12.41 yuan, indicating potential for a price correction if it fails to break through this level [6]. Dividend Information - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Shareholder Structure - As of September 30, 2025, Haiprime had 27,000 shareholders, with the Hong Kong Central Clearing Limited being the eighth largest shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - The pharmaceutical sector is experiencing active trading, with innovative drugs and biovaccines showing strong performance, indicating a positive outlook for the industry through 2026 [1] Industry Summary - The pharmaceutical sector has seen significant stock price increases, with companies like Chengda Pharmaceutical, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching a 20% limit up, while others like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also hit the limit up [1] - CITIC Securities forecasts that the investment trend in the pharmaceutical industry will continue to be driven by the concentration of innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices, leading to a stable domestic market environment [1] - The industry is expected to return to a market pricing system based on clinical value and demand, which will contribute to a stable and continuous growth trend in the performance of listed companies [1] Investment Strategy - The pharmaceutical industry is recommended for continued overweight positioning, with suggested investment themes for 2026 including: 1. Innovation-driven and internationalization, focusing on companies that are innovating and expanding internationally in a favorable domestic policy environment [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports due to geopolitical risks [1] 3. New policies and new opportunities, targeting companies benefiting from optimized procurement, medical insurance payment reforms, consumption stimulus policies, and state-owned enterprise reforms [1]

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - The company is actively engaged in the development of early-stage products, with several expected to enter critical registration clinical trials by 2025 [2] - The company’s revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] Group 2: Recent Developments - Junshi Biosciences is collaborating with various research institutions and universities to develop vaccines, including those for monkeypox and Zika, which are currently in preclinical development [3] - A partnership has been established with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3] Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06%, while the net profit attributable to the parent company was -596 million yuan, a 35.72% increase year-on-year [8] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% [8] Group 4: Market Activity - On November 13, Junshi Biosciences' stock rose by 2.38%, with a trading volume of 341 million yuan and a turnover rate of 1.14%, bringing the total market capitalization to 40.246 billion yuan [1] - The stock has seen a net inflow of 34.14 million yuan from major investors, indicating a slight increase in institutional interest [4][5]

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Group 1: Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The company’s main business segments include heparin, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of September 30, 2025, Haiprime reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Group 2: Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Haiprime has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Activity - On November 12, Haiprime's stock rose by 0.16%, with a trading volume of 39.42 million yuan and a turnover rate of 0.26%, bringing the total market capitalization to 18.165 billion yuan [1]. - The stock has seen a net outflow of 534,600 yuan from major investors today, indicating a reduction in holdings over the past three days [4][5].

Core Viewpoint - The news highlights the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., emphasizing its strong international revenue and the impact of RMB depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 10, the stock price of Hepalink increased by 0.90%, with a trading volume of 45.0469 million yuan and a turnover rate of 0.29%, bringing the total market capitalization to 18.15 billion yuan [1]. - The stock has seen a net outflow of 1.201 million yuan from major funds today, indicating a lack of strong buying interest [4][5]. Technical Analysis - The average trading cost of the stock is 11.57 yuan, with the current price near a support level of 12.33 yuan, suggesting potential for a rebound if this level holds [6].

Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].